Weird someone just posted this link about a Triton deal being cancelled
Well a few red flags there already!
A few. SG&A exceeds R&D by a wide margin. NBIO's cash of $5K won't go far in testing a monoclonal Ab, even in Phase 1. They are still finishing up on pre-clinical. Their Ab seems reasonable at face value. However, their diving onto the Covid bandwagon smells. As in way too late, and would take too long.
Their deal with Triton was strange. Triton was going to act as an underwriter??? Very confusing. Maybe JS or Integral can look at what was cancelled.
Market Data 
Markets 
AI
